Model has given entry signals for CSL Limited: - CSL Limited is a global specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. - We are very excited about opportunities in the biotech sector, as we believe the fight against COVID is going to move to the next phase in...
GALT reported positive results for cancer immunotherapy one week ago. This was followed by algorithm trading taking the stock price lower. There is high open interest on $3, $4, and $5 calls expiring today. The price should reverse and move higher with the expiration of these calls, since the options traders accomplished what they were after to keep below the...
OCGN kind of treading water for now. I think what we need to see are some rock-solid results from COVAXIN, which this rolling submission could be helpful in identifying. The Phase 3 results were interesting. With more warnings coming out about the current SOC EAU vaccines, another option might not be "too late" at this point. But a lot will clearly come down to...
Broke one downtrend one more to go. Soon be sooner than later.
$SRNE has bounced off of the .618 fib level, which could mean a break to the recent high. I am anticipating a touch to the $15 zone within the next couple of months. Good Luck!
Looking to place some Leaps on FATE as hedge funds pile up on this biotech stock
Looking to place some longs on ARGX. Argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer. argenx serves customers in the Netherlands and Belgium.n top 10: 10 8 25.0% 6 (0.35%) 6 (0.35%) 0.0% Funds Holding: 185 170 8.82% 63 (3.7%) 55 (3.19%) 14.55% 13F shares: 28.505...
lol if this pans out greatest gains ever
Since 1969 BMY has been around yes. The fact this is chartable is wild. I think we see 70+ in 2-3 weeks 80+ after that new all time highs. I already am accumulating 700+ OTM options.
The thing about SENS is that it's been a company crushing it in 2021. When it was first discussed this year it was still trading below $1. Despite recent volatility, it's up significantly year-to-date. I think volume remains steady but definitely on the lower end of the range. But good data from the last presentation on its PROMISE study seems to have sparked...
No there is nothign wrong with this stock its a typical bio downtrend. I think this is due for a massssssssive move. I actually rarely pay much attention to indicators regardless how many I have / most the time zoomed in double clicked in just using volume etc. However, to find end of long term downtrends they can be extremely useful on these. Bollinger Bands...
ProShares Ultra Nasdaq Biotechnology seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®.
All, I think this has a massive play possible here. Why: -Confleunce support (horizontally) + trend support -Falling wedge downtrend -40MA tight against trend (if you're a VWAP person I'm sure you would see a VWAP play) -RSI/MACD both good Recent news very positive. Looking into options Monday.
PIRS Pieris Pharmaceuticals has collaboration agreements with AstraZeneca, Boston Pharmaceuticals, Servier, Seagen and Genentech, part of Roche. AZN AstraZeneca 70Mil upfront payment and 5.4Bil potential milestone payments Boston Pharmaceuticals 10Mil upfront payment and 353Mil potential milestone payments Genentech member of RHHBY Roche Group 20Mil upfront...
The Biotech company Evaxion Biotech, EVAX, who develop drugs based on AI platforms, is poised to publish data from its phase 1/2a trials of EVX-01 and EVX-02 in the first half of 2021. According to Yahoo Finance there are currently two analysts with price targets for the share, $18 and $23. Evaxion is an AI-immunology platform company decoding the human immune...
Well, doesn't this look familiar? ITRM tested is previous level of support AND resistance in a wide channel today. IDK what the sell-off was but I'm guessing the re-entry had something to do with speculation on the FDA data set to come out next month. "At the end of May, Iterum provided an update on its New Drug Application with the U.S. Food and Drug...
$CARA Target 17.68 for 24.42% Or double position at 10.74 I'm not sure if I published this one when I first bought on that hellacious dip, haha. 🤣 Anyway, it looks like it found a little bit of support here so, might as well publish it here This might not be a trade you want to play... I will post better ones... just for reference here. — On the far right of...
*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* My team has been following clinical-stage biotech company $LCTX for the past...